{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:29:58Z","timestamp":1786987798922,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C1491\/A25351"],"award-info":[{"award-number":["C1491\/A25351"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CTUQQR-Dec 22\/100004"],"award-info":[{"award-number":["CTUQQR-Dec 22\/100004"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CRUK\/07\/015"],"award-info":[{"award-number":["CRUK\/07\/015"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007406","name":"Fundaci\u00f3n BBVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ebiom.2025.105823","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T23:27:36Z","timestamp":1752881256000},"page":"105823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+\/HER2+ early breast cancer: a POETIC translational study"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-2711","authenticated-orcid":false,"given":"Milana Bergamino","family":"Sirv\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"L\u00f3pez-Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3477-3426","authenticated-orcid":false,"given":"Xixuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Tovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Kilburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Holcombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Skene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Alataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-2810","authenticated-orcid":false,"given":"Eugene F.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Dowsett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-2501","authenticated-orcid":false,"given":"Maggie Chon U.","family":"Cheang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"33","key":"10.1016\/j.ebiom.2025.105823_bib1","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105823_bib2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10075","key":"10.1016\/j.ebiom.2025.105823_bib3","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105823_bib4","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/1078-0432.CCR-22-1092","article-title":"Pertuzumab, Trastuzumab, and an aromatase inhibitor for HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer: PERTAIN final analysis","volume":"29","author":"Arpino","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105823_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100088","article-title":"Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis","volume":"6","author":"Peleg Hasson","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105823_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41523-023-00509-2","article-title":"Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive\/HER2-positive BC: analysis from the phase III randomized ShortHER trial","volume":"9","author":"Dieci","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105823_bib7","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","article-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","volume":"21","author":"Smith","year":"2020","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.ebiom.2025.105823_bib8","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/JCO.2005.01.4829","article-title":"Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study","volume":"23","author":"Dowsett","year":"2005","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ebiom.2025.105823_bib9","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2005.04.3034","article-title":"Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole","volume":"24","author":"Ellis","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105823_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamaoncol.2023.7304","article-title":"Tumor intrinsic subtypes and gene expression signatures in early-stage ERBB2\/HER2-positive breast cancer: a pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials","volume":"10","author":"Fernandez-Martinez","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105823_bib11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2016.3824","article-title":"RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial","volume":"3","author":"Fumagalli","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105823_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-019-05398-3","article-title":"Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination","volume":"178","author":"Swain","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ebiom.2025.105823_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104205","article-title":"HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+\/HER2+ breast cancer","volume":"83","author":"Bergamino","year":"2022","journal-title":"eBioMedicine"},{"issue":"1-2","key":"10.1016\/j.ebiom.2025.105823_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ans.15487","article-title":"Window of opportunity treatment in breast cancer","volume":"90","author":"Chen","year":"2020","journal-title":"ANZ J Surg"},{"issue":"22","key":"10.1016\/j.ebiom.2025.105823_bib15","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105823_bib16","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6797","key":"10.1016\/j.ebiom.2025.105823_bib17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105823_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105823_bib19","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2007.12.9437","article-title":"Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial","volume":"26","author":"Dowsett","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105823_bib20","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1200\/JCO.2005.07.559","article-title":"Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists","volume":"23","author":"Dowsett","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2025.105823_bib21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3389\/fonc.2019.00707","article-title":"PAM50 subtypes in baseline and residual tumors following neoadjuvant Trastuzumab-based chemotherapy in HER2-positive breast cancer: a consecutive-series from a single institution","volume":"9","author":"Pernas","year":"2019","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105823_bib22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","article-title":"HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial","volume":"18","author":"Llombart-Cussac","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105823_bib23","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1245\/s10434-017-5863-x","article-title":"Pertuzumab\/Trastuzumab\/CT versus trastuzumab\/CT therapy for HER2+ breast cancer: results from the prospective neoadjuvant breast registry symphony trial (NBRST)","volume":"24","author":"Beitsch","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"10.1016\/j.ebiom.2025.105823_bib24","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.3390\/cancers13194884","article-title":"Immune markers and tumor-related processes predict neoadjuvant therapy response in the WSG-ADAPT HER2-positive\/hormone receptor-positive trial in early breast cancer","volume":"13","author":"Harbeck","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105823_bib25","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdz055","article-title":"De-escalated therapy for HR+\/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study","volume":"30","author":"Guarneri","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105823_bib26","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/1078-0432.CCR-21-2718","article-title":"Impact of duration of neoadjuvant aromatase inhibitors on molecular expression profiles in estrogen receptor-positive breast cancers","volume":"28","author":"Bergamino","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2025.105823_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13294","article-title":"Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation","volume":"7","author":"Gellert","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105823_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103987","article-title":"HER2DX genomic test in early-stage HER2-positive breast cancer","volume":"9","author":"Tolaney","year":"2024","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105823_bib29","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/cancers11101618","article-title":"A comprehensive review on MAPK: a promising therapeutic target in cancer","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105823_bib30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10549-010-0887-y","article-title":"Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer","volume":"121","author":"Mello-Grand","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105823_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13058-019-1176-2","article-title":"Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes","volume":"21","author":"Sobral-Leite","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"17","key":"10.1016\/j.ebiom.2025.105823_bib32","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1158\/1078-0432.CCR-08-0555","article-title":"Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response","volume":"14","author":"Helleman","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105823_bib33","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1038\/s41467-023-39613-z","article-title":"Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers","volume":"14","author":"Schuster","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105823_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41523-022-00426-w","article-title":"Mutual exclusivity of and mutations in endocrine resistant metastatic breast cancer","volume":"8","author":"Li","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105823_bib35","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1016\/j.clbc.2023.07.006","article-title":"Risk-based therapeutic strategies for HER2-positive early breast cancer: a consensus paper","volume":"23","author":"Garutti","year":"2023","journal-title":"Clin Breast Cancer"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425002671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425002671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:39:43Z","timestamp":1778873983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425002671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"alternative-id":["S2352396425002671"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105823","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+\/HER2+ early breast cancer: a POETIC translational study","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105823","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105823"}}